

# Introduction & Notes re: MVB Annual Assessment Setting Workbook

MVB Calendar Year 2020

[Note: This is Final Working Version as of 9/25/2019.]

01. This workbook follows the past naming conventions with each sheet beginning with a letter (i.e., "a." through "d."), and each cell within each sheet being identified by a 2-digit row number (e.g., "01.") and column letter (e.g., "A"). So, to facilitate reference while collaborating via conference phone, users can refer to any single number, for example the new assessment rate, by a combination of the above. For that key number, the new monthly assessment rate, the reference is "a.26.C".
02. Since the first measurement period is for the month of January and assessments are due forty-five (45) days after the end of each quarter, the first assessment payment with the new rate will be May 15, 2020 for the months of Jan-Mar, 2020.
03. The primary spreadsheet for the work is the assessment calculation worksheet, worksheet a. The other sheets are intended to be reference or to develop background data in specific areas for the work. Key data for developing the primary funding target is on spreadsheet b. which contains data supplied by the Maine CDC for the vaccine funding needs. Key numbers from a subsidiary sheet rolled into the main assessment sheet generally are shaded in yellow.
04. These spreadsheets have Board controls. This is intended to help users test various assumptions and control points which may be adjusted by the MVB in setting the final new rate. Those cells in which entries normally would be made are shaded in green. For example, a user can adjust utilization assumptions for increases over prior years by entering percent's either by vaccine on sheet b. or overall on sheet a (a.3.D). The vaccine funding target takes the number as adjusted by those two factors and then applies the assumed cost increase (a.4.D). The cost increase is applied for 9/12 of the year since it typically becomes effective as of April 1 each year.
05. Because the first collections of the year (due February 15) will still be at the old rate and based upon covered lives reported for Oct-Dec 2019, this spreadsheet first deducts that quarterly collection and then calculates the new rate based upon what is needed to hit the funding target over the remaining 9 months.
06. It is anticipated that the MVB will, as part of its deliberations and upon considering the input of any public members or others at its meeting(s), adjust the assumptions which guide the assessment level. Of course, the MVB may also determine to adjust the assessment setting process itself or this workbook structure at any time.

# Maine Vaccine Board

## 2020 Calendar Year Assessment Calculation

Column →	A	B	C	D	E
Line ↓	2019		2020		
<b>A. Preliminary Vaccine Cost, Projection Parameters, &amp; Population Estimates</b>					
01.	\$11,324,363		\$13,627,265		State Fiscal Year Vaccine Estimate (from tab b.)
02.	140,088		139,739		Estimate of Covered Lives including Tricare(Covered Lives tab c.)
03.	\$113,244	1.0%	\$136,273	1.0%	Provision for Vaccine Utilization increase
04.	\$403,176	4.7%	\$227,098	2.2%	Vaccine cost inflation factor (prices change each April 1st)
05.	\$11,840,782		\$13,990,636		<sup>1</sup> Calendar Year Vaccine Funding Estimate
<b>B. Budget Estimates</b>					
06.	\$149,040		\$149,040		<sup>3</sup> Servicing Agent Contract for Administrative Services
07.	\$6,000		\$6,000		Audit Fee (Move to paid public auditor & 2 years catch up fees)
08.	\$6,000		\$7,000		Bank Fees (adding TD Bank Lockbox including setup expenses)
09.	\$5,500		\$10,500		Legal (services of AG's office only estimated)
10.	\$166,540		\$172,540		Total Operating Costs Projected
<b>C. Financial Carry Forwards</b>					
11.	\$9,830,939		\$6,647,318		Estimated Starting Balance January 1
12.	\$5,749,100	6.4	\$3,284,574	3.00	Amount Retained for Liquidity Reserve - 3.0 months of non flu
13.	\$1,061,220		\$852,342		Amount Retained for Liquidity Reserve - full annual flu cost
14.	\$3,020,620		\$2,510,402		Carryforward used to reduce current assessment calculation
<b>D. Aggregate Annual Assessment Calculation</b>					
15.	\$11,840,782		\$13,990,636		Costs of Vaccines Provided
16.	\$166,540		\$172,540		Total Operating Costs
17.	\$0		\$0		Other (as approved by board -- see statute section 2.M)
18.	\$12,007,322		\$14,163,176		"Total Costs of the Fund" per statute section 2.M.
19.	\$42,026	0.35%	\$49,571	0.35%	Collection Losses (i.e. assumed "bad debt expense")
20.	-\$68,235		-\$104,845		<sup>2</sup> Interest Income
21.	-\$3,020,620	-25.2%	-\$2,510,402	-17.7%	(excess) or shortfall of cash from prior operating year
22.	\$270,165	2.25%	\$318,671	2.25%	add reserve up to 10% per statute section 5.A.(3).
23.	\$9,230,658		\$11,916,171		Total Assessments Needed
24.	-\$3,484,950		-\$1,910,462		Projected assessments February 15 at old rate
25.	\$5,745,708		\$10,005,709		Total Assessments Needed at new rate
<b>E. Per Covered Life Assessment Calculation</b>					
26.	\$54.69		\$95.47		<b>Annual Assessment per Covered Life</b>
27.	\$4.56		\$7.96		<b>Monthly Assessment per Covered Life</b>
28.	-5.6%		20.3%		% Change in Vaccine Costs
29.	-45.04%		74.6%		% Change in Assessment
<b>F. Note: Total Assessed as % of Hard Vaccine Costs</b>					
30.	-22.04%		-14.8%		All-in costs % above vaccine costs
<b>G. Indicated Monthly Assessment Level next year apart from reserve / cash changes</b>					
31.	\$6.33		\$8.93		<sup>4</sup> Preliminary Assessment projection
Notes			12.3%		Increase in preliminary assessment projection
<sup>1</sup> Maine CDC + per vaccine adjustments + utilization increase with inflation factor.					
<sup>2</sup> Used the average of the five most recent year's Investment Income from audited financials.					
<sup>3</sup> Fixed price contract all inclusive of expenses.					
<sup>4</sup> Projection: annual amounts w/ carryforward cash, reserve changes, and 1 more year of inflation & utilization changes.					

Maine CDC Vaccine Projection Data

Column →  
Line ↓

Line ↓	A	B	C	D			E			F			G			H			I			J			K		
				Prior Year Actuals			Federal FY 20 Estimates			Vaccine Level Adjustments			Vaccine Funding Target														
Vaccine	Brand Name	NDC	Cost Per Dose	Doses	Cost	Cost Per Dose	Doses	Cost	Vaccine Level Adjustments	Vaccine Funding Target																	
01.	DAPTACEL	Sanofi Pasteur	49281-0286-10	\$ 17.61	4018	\$ 70,756.98	\$18.07	6,765	\$122,244	0.00%	\$122,244																
1.b				\$ 18.07	1141	\$ 20,617.87																					
02.	PENTACEL	Sanofi Pasteur	49281-0510-05	\$ 58.33	7652	\$ 446,341.16	\$59.42	9,940	\$590,635	0.00%	\$590,635																
2.b				\$ 59.42	2626	\$ 156,036.92																					
03.	QUADRACEL	Sanofi Pasteur	49281-0562-10	\$ 39.57	1581	\$ 62,560.17	\$40.67	1,858	\$75,565		\$75,565																
3.b				\$ 40.67	823	\$ 33,471.41																					
04.	IPOL (EIPV)	Sanofi Pasteur	49281-0860-10	\$ 13.30	1690	\$ 22,477.00	\$13.55	4,118	\$55,799	0.00%	\$55,799																
4.b				\$ 13.55	684	\$ 9,268.20																					
05.	Menactra (MCV4)	Sanofi Pasteur	49281-0589-05	\$ 91.81	9056	\$ 831,431.36	\$93.45	19,822	\$1,852,366	0.00%	\$1,852,366																
5.b				\$ 93.45	2536	\$ 236,989.20																					
06.	ACTHIB (HIB)	Sanofi Pasteur	49281-0545-03	\$ 9.23	4177	\$ 38,553.71	\$9.48	6,577	\$62,350	0.00%	\$62,350																
6.b				\$ 9.48	1557	\$ 14,760.36																					
07.	ADACEL (Tdap)	Sanofi Pasteur	49281-0400-10	\$ 30.89	1569	\$ 48,466.41	\$31.75	4,826	\$153,226	0.00%	\$153,226																
7.b				\$ 31.75	646	\$ 20,510.50																					
08.	TENIVAC	Sanofi Pasteur	49281-0215-15	\$ -	0	\$ -	\$20.61	500	\$10,305		\$10,305																
8.b				\$ -	0	\$ -																					
09.	TRUMENBA (Menb)	Pfizer	00005-0100-10	\$ 104.79	137	\$ 14,356.23	\$108.95	342	\$37,261	\$0.00	\$37,261																
9.b				\$ 108.95	51	\$ 5,556.45																					
10.	Prevnar 13 (PCV 13)	Pfizer	00005-1971-02	\$ 131.77	15452	\$ 2,036,110.04	\$137.01	16,280	\$2,230,523	\$0.00	\$2,230,523																
10.b				\$ 137.01	5268	\$ 721,768.68																					
11.	Bexsero (Menb)	GlaxoSmithKline	58160-0976-06	\$ 129.06	184	\$ 23,747.04	\$108.53	2,500	\$271,325	0.00%	\$271,325																
11.b				\$ 103.40	757	\$ 78,274																					
11.c				\$ 102.33	434	\$ 44,411																					
12.	MENVEO (MCV4)	GlaxoSmithKline	58160-0955-09	\$ 92.10	316	\$ 29,104	\$76.00	5,058	\$384,408		\$384,408																
12.b				\$ 73.83	1903	\$ 140,498																					
12.c				\$ 94.84	759	\$ 71,984																					
13.	Infanrix (DTaP)	GlaxoSmithKline	58160-0810-11	\$ 18.19	461	\$ 8,386	\$18.67	499	\$9,316	0.00%	\$9,316																
13.b				\$ 18.67	55	\$ 1,027																					
14.	Pediarix (DTaP/Hep B/IPV)	GlaxoSmithKline	58160-0811-52	\$ 57.97	4827	\$ 279,821	\$59.05	5,027	\$296,844	0.00%	\$296,844																
15.	Kinrix (DTaP/IPV)	GlaxoSmithKline	58160-0812-52	\$ 40.19	2181	\$ 87,654	\$41.31	2,778	\$114,759	0.00%	\$114,759																
15.b				\$ 41.31	1088	\$ 44,945																					
15.c				\$ 41.31	327	\$ 13,508																					
16.	Havrix (Hep A)	GlaxoSmithKline	58160-0825-11	\$ 19.58	4953	\$ 96,980	\$20.52	11,407	\$234,072	0.00%	\$234,072																
16.b				\$ 19.58	4835	\$ 94,669																					
16.c				\$ 20.52	3151	\$ 64,659																					
17.	Engerix-B (Hep B)	GlaxoSmithKline	58160-0820-52	\$ 14.03	2006	\$ 28,144	\$16.02	4,066	\$65,137	0.00%	\$65,137																
17.b				\$ 16.02	3212	\$ 51,456																					
18.	Rotarix (Rota)	GlaxoSmithKline	58160-0854-52	\$ 92.85	2653	\$ 246,331	\$94.69	3,096	\$293,160	0.00%	\$293,160																
18.b				\$ 94.69	1015	\$ 96,110																					
19.	Boostrix (TDaP)	GlaxoSmithKline	58160-0842-11	\$ 31.37	4070	\$ 127,676	\$32.24	8,428	\$271,719	0.00%	\$271,719																
19.b				\$ 32.24	494	\$ 15,927																					
19.c				\$ 32.24	987	\$ 31,821																					
20.	HIBERIX	GlaxoSmithKline	58160-0818-11	\$ 9.65	34	\$ 328	\$9.46	32	\$303	0.00%	\$303																
20.b				\$ 9.46	15	\$ 142																					
21.	VAQTA (Hep A)	Merck Sharp & Dohme Corp.	00006-4831-41	\$ 19.29	2953	\$ 56,963	\$19.66	3,054	\$60,042	0.00%	\$60,042																
21.b				\$ 19.66	511	\$ 10,046																					
22.	RECOMBIVAX (Hep B)	Merck Sharp & Dohme Corp.	00006-4981-00	\$ 12.30	3543	\$ 43,579	\$12.30	7,522	\$92,521	0.00%	\$92,521																
22.b				\$ 12.30	1873	\$ 23,038																					
23.	PedvaxHib (Hib)	Merck Sharp & Dohme Corp.	00006-4897-00	\$ 13.09	2928	\$ 38,328	\$13.21	3,605	\$47,622	0.00%	\$47,622																
23.b				\$ 13.21	1023	\$ 13,514																					
24.	Gardasil (HPV9)	Merck Sharp & Dohme Corp.	00006-4119-03	\$ 168.10	2709	\$ 455,383	\$178.14	17,158	\$3,056,526	0.00%	\$3,056,526																
24.b				\$ 168.10	7194	\$ 1,209,311																					
24.c				\$ 158.06	795	\$ 125,658																					
24.d				\$ 178.14	3678	\$ 655,199																					
25.	ROTATEQ (Rota)	Merck Sharp & Dohme Corp.	00006-4047-41	\$ 70.49	8767	\$ 617,986	\$70.49	6,337	\$446,695	0.00%	\$446,695																
26.	MMR II	Merck Sharp & Dohme Corp.	00006-4681-00	\$ 21.05	4862	\$ 102,345	\$21.22	5,931	\$125,856	0.00%	\$125,856																
26.b				\$ 21.22	2323	\$ 49,294																					
27.	Proquad (MMRV)	Merck Sharp & Dohme Corp.	00006-4171-00	\$ 125.11	4850	\$ 606,784	\$131.40	8,578	\$1,127,149	0.00%	\$1,127,149																
27.b				\$ 131.40	1930	\$ 253,602																					
28.	Pneumovax23 (Pedi)	Merck Sharp & Dohme Corp.	00006-4943-00	\$ 53.11	22	\$ 1,168	\$56.14	113	\$6,344	0.00%	\$6,344																
28.b				\$ 56.14	12	\$ 674																					
29.	Varivax	Merck Sharp & Dohme Corp.	00006-4827-00	\$ 98.24	3640	\$ 357,594	\$104.09	6,541	\$680,853	0.00%	\$680,853																
29.b				\$ 104.09	230	\$ 23,941																					
30.	Fluzone PF 0.5ml (>3 yrs)	Sanofi Pasteur	49281-0419-50	\$ 15.11	12830	\$ 193,861	\$13.76	3,000	\$41,271	0.00%	\$41,271																
31.	Fluzone PF 0.25ml (<3 yrs)	Sanofi Pasteur	49281-0519-25	\$ 15.11	8970	\$ 135,537	\$13.76	25,700	\$353,555	0.00%	\$353,555																
32.	FluMist Sprayer, 10-pack (2-18)	Astra Zeneca	66019-0306-10	\$ 18.88	2600	\$ 49,088	\$18.88	1,280	\$24,166	0.00%	\$24,166																
33.	Flulaval PF 0.5ml (6mth+)	GlaxoSmithKline	19515-0906-52	\$ 13.50	48330	\$ 652,455	\$13.50	32,100	\$433,350	0.00%	\$433,350																
34.						\$ 12,244,553			\$13,627,265	0.00%	\$13,627,265																
35.	<b>TOTAL</b>				<b>229,763</b>	<b>\$ 12,244,553</b>		<b>234,838</b>	<b>\$13,627,265</b>		<b>\$13,627,265</b>																
36.									Adjusted for overall utilization increase		\$13,763,538																
37.									Adjusted for price increase		\$13,990,636																

**Maine Vaccine Board  
Vaccine Assessment Change Walk Down**

Column →	A	B	C	D	E	F	G
Line ↓	<b>2020 Calendar Year Assessment Calculation</b>						
				<u>Change from Prior Year</u>			<u>Walk Down</u>
	<u>Prior Year</u>	<u>2,020</u>	<u>Aggregate \$</u>	<u>Distribution</u>	<u>Per Enrollee</u>		
01. Estimated vaccine costs	\$11,840,782	\$13,990,636	\$2,149,854	50.5%	\$1.71		37.5%
02. Total operational costs	\$166,540	\$172,540	\$6,000	0.1%	\$0.00		0.1%
03. Bad debt and investment income	-\$26,209	-\$55,274	-\$29,065	-0.7%	-\$0.02		-0.5%
04. Net working capital reserve/carry forward	-\$2,750,455	-\$2,191,731	\$558,724	13.1%	\$0.44		9.7%
05. Projected assessment at old rate	<u>-\$3,484,950</u>	<u>-\$1,910,462</u>	<u>\$1,574,488</u>	<u>37.0%</u>	<u>\$1.25</u>		<u>27.5%</u>
06. Total	\$5,745,708	\$10,005,709	\$4,260,001	100.0%	\$3.39		74.3%
07. Covered Lives	140,088	139,739	-349				0.2%
08. Total							74.6%
09. Assessment	\$4.56	\$7.96				\$3.40	74.6%